• Jobs
  • Startups
  • Hire
LoginSign up

Odyssey Therapeutics

Odyssey Therapeutics has 4 open roles. Stated pay range: $121k – $300k a year. Last round: Series D, $213M, Sep 10, 2025.

Open roles

  • Odyssey Therapeutics logo
    Principal Scientist/Associate Director, Process Chemistry

    Odyssey Therapeutics

    • Boston, MA
    • On-site · Principal
    • $121k–$182k
    Rippling
    Posted 37d ago
  • Odyssey Therapeutics logo
    Senior Director, Clinical Operations

    Odyssey Therapeutics

    • Boston, MA
    • On-site · Director / Executive
    • $177k–$265k
    Rippling
    Posted 45d ago
  • Odyssey Therapeutics logo
    Director/Senior Director, IT

    Odyssey Therapeutics

    • Boston, MA
    • On-site · Director / Executive
    • $143k–$264k
    Rippling
    Posted 59d ago
  • Odyssey Therapeutics logo
    Executive Director, Biologics DMPK & Translational Sciences

    Odyssey Therapeutics

    • Boston, MA
    • On-site · Director / Executive
    • $200k–$300k
    Rippling
    Posted 65d ago

About

Odyssey Therapeutics logo

Odyssey Therapeutics

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

Private companyIn the news
Founded2021
Size118 employees
IndustryBiotechnology Research
Unlock human wisdom
ThesisTermsPrivacy
Funding
  • Series D · $213M · Sep 10, 2025
News
  • Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
  • Odyssey Therapeutics publishes TNFR2 agonism research in immunology journal
  • Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Claim odysseytx.com

Work at odysseytx.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.